MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
about
Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantationMycophenolate mofetil versus methotrexate for prevention of acute graft-versus-host disease in patients receiving allogeneic hematopoietic stem cell transplantationPossible implication of bacterial infection in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantationEnteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT.Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationAllogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity.Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignanciesImpact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.Pathophysiology of GvHD and Other HSCT-Related Major Complications.Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.Cyclosporine Plus Methotrexate or Cyclosporine Plus Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Acute Leukemia Transplant: Comparison of Toxicity, Engraftment Kinetics and Transplant Outcome.The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.Substitution of methotrexate with corticosteroid for acute graft-versus-host disease prevention in transplanted patients who develop methotrexate toxicity.Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation.Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc- mouse model.Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation.Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.
P2860
Q24194807-78C9145B-D980-4474-9FD2-A310EC5C31FCQ24202699-9EBEDE52-31E9-48A4-948C-A34F760A37DEQ27001015-7542727B-78C4-4009-A874-6B73EDCB1F7EQ30315933-9DEE5BBE-CA75-4FE1-B18D-2CB0DDF551C7Q35499395-9191D2FB-9F69-4529-BF79-C9A4EB9A97FCQ35571053-1FCE1AFF-A7AB-4D1E-BDF0-A3B17565C5ECQ36577708-3E66E10E-602E-4B47-809E-0C66011897D1Q36662017-16333290-DB3F-4AD0-B99C-F870EC38B910Q37592994-573C18AE-189E-4BFF-8BD5-AF5589FA1D0DQ37710572-D343A1ED-5AE4-45B2-99E6-EB70F728830BQ38010596-2D8E9092-E043-4A85-B3B1-29D81B5DF247Q40096414-8B289B62-9D82-4922-B425-BA78B5C3F82DQ40396484-7EAFCD6B-8EAC-4729-95C2-D7875C9D88A6Q40874306-6FE91514-ADDF-4994-A6D2-1EAA7200085DQ41525058-171D0312-E8C4-4D74-9083-B4151AC59261Q43847839-65949B5B-03E4-4743-A704-F9F9198110B0Q45910300-17FA1616-A8FE-4951-B5EF-F2760D7D9269Q47436824-DA1F39C8-B73C-4BEF-AF6A-4E9ACF54BDF0Q52814358-EC3557C1-597C-4F9E-8B57-19C81A5B1334Q54692075-9B642F35-3401-4C2B-8302-ADB9C616386D
P2860
MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
MTX or mycophenolate mofetil w ...... T from HLA-identical siblings.
@en
MTX or mycophenolate mofetil w ...... T from HLA-identical siblings.
@nl
type
label
MTX or mycophenolate mofetil w ...... T from HLA-identical siblings.
@en
MTX or mycophenolate mofetil w ...... T from HLA-identical siblings.
@nl
prefLabel
MTX or mycophenolate mofetil w ...... T from HLA-identical siblings.
@en
MTX or mycophenolate mofetil w ...... T from HLA-identical siblings.
@nl
P2093
P2860
P356
P1476
MTX or mycophenolate mofetil w ...... T from HLA-identical siblings.
@en
P2093
C Martínez
D Valcárcel
E Carreras
F Fernández-Avilés
J L Piñana
P2860
P2888
P304
P356
10.1038/BMT.2009.362
P407
P577
2010-02-08T00:00:00Z
P5875
P6179
1025829761